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Particulate platforms capable of delivering multiple actives while providing diagnostic features 
have gained considerable interest over the last few years. In this study, magnetic polymer yolk-
shell particles (YSPs) were engineered using a tri-needle coaxial electrospraying technique 
enabling dual-mode (ultrasonic and magnetic resonance) imaging capability with specific multi-
drug compartments via an advanced single-step encapsulation process. YSPs comprised 
magnetic Fe3O4 nanoparticles (MNPs) embedded in the polymeric shell, an interfacing oil layer 
and a polymeric core (i.e. composite shell-oil interface-polymeric core). Ultrasound backscatter 
signal frequency was modulated through YSP loading dosage, and both T1 and T2 weighted MRI 
signal intensities were shown to reduce with increasing MNP content (YSP outer shell). Three 
fluorescent dyes (selected as model probes with varying hydrophobicities) were co-encapsulated 
separately to confirm YSP structure. Probe release profiles were tuned by varying power or 
frequency of an external auxillary magnetic field (AMF, 0.7 mT (LAMF) or 1.4 mT (HAMF)). 
In addition, an “inversion” phenomenon for AMF-enhanced drug release process was captured 
and is reported. Low YSP cytotoxicity (5mg/ml) and biocompatibility (murine, L929) was 
confirmed. In summary, magnetic YSPs demonstrate timely potential as multifunctional 
theranostic agents for dual-imaging modality and magnetically controlled co-active delivery. 
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    Particles exhibiting combined diagnostic (e.g. imaging) and therapeutic (controlled or 
triggered active release) functions are extremely valuable to address several global healthcare 
challenges; with extensive recent efforts focusing on tumor targetting, personalized medicine and 
biomedical engineering.
1-2
 Such particles enable a single carrier system to provide real-time 
disease diagnosis in-vivo as well as fine-tune active release at a specific location in timely 
fashion. This multi-faceted approach, in lieu, has propelled them as emerging paradigms for 
clinical practice.
3-5
  Furthermore, the functionality of such particles goes beyond image-guided 
drug delivery; in that rapid assessment and treatment of disease is accomplished at an early stage 
whilst minimizing unwanted cytotoxic side-effects often arising from conventional strategies.
6-7
  
Magnetic resonance imaging (MRI) is a pain-free and safe diagnostic procedure that has 
numerous advantages over other routine imaging methods including excellent anatomic detail, 
exquisite soft tissue contrast, high spatial resolution and multi-planar imaging capacity.
8-9
 MRI 
signal is dependent on longitudinal (T1) and transverse (T2) proton relaxation times of water 
(mainly) and therefore; differences arising in these values provide variable contrast in images. 
MRI contrast agents are able to decrease T1 and T2 relaxation times, and subsequently improve 
contrast between normal and diseased tissues.
10-11
 Furthermore, because of their interaction with 
magnetic fields, contrast agents have also been used to control active agent release from co-
encapsulated or co-embedded systems via an auxiliary magnetic field (AMF).
12
 In contrast, 
ultrasound (US) is a well-established and widely used clinical imaging modality. This technique 
provides real time imaging, particularly for blood flow, and several advantages relating to cost 





While both of these imaging modalities are essential in present and emerging diagnostic 
technologies, MRI and US have their own limitations. For instance, MRI is not applicable for 
real-time imaging and also requires a relatively longer time period for image acquisition.
9
 US 
imaging provides lower resolution and penetration depth, which hinders its ability to 
discriminate between superficial and echogenic structures.
8
  In this regard, the development of a 
dual-imaging modality technique, combining both MRI and US, will be timely and enables much 
needed advance from either platform. Moreover, to maximize the merits of an integrated imaging 
technique; design and construction of effective and viable contrast agents suitable for both 
modalities will be of significance.
7, 9
  
In recent times, encapsulation and delivery of multiple drugs from a single dosage form 
platform is considered to be crucial for patient compliance and advanced therapies. For example, 
combination of anti-inflammatory and anti-cancer drugs in a single cargo is promising for cancer 
therapy since targeting inflammation, in addition to restricting replication, further reduces tumor 
development and progression.
14
 Therefore, co-encapsulation of two or more actives has potential 
to deliver synergistic therapeutic effects and reduced side-effects.
15
 Furthermore, the possibility 
to co-encapsulate hydrophilic and hydrophobic drugs in a single dosage form is ideal for drug 
dispersibility, active release and therapeutic impact
16
. Several co-formulation strategies become 
resticted due to complexities surrounded active hydrophobicity, formulation, retention and 
delivery. 
Developments in synergistic therapies (multi-drug dosing) have yielded numerous 
explorations and formulations which provide multiple active delivery from a single cargo.
17-18
 
One such area of focus has centered on encapsulated polymeric particulate systems; with 




 Among all polymeric particulate formats with compartmentalized (interior) structures, yolk-
shell particles (YSPs) appear least explored although they display unique features and physical 
properties; including low densities, large surface areas and excellent loading capacities.
22
 
Limited data shows the design and development of functionalized YSP interior core and outer 
shell have potential to enhance drug delivery, although the vast majority of related research to 
date has focused on inorganic materials (including silica and carbon based).
23
 In this regard, 
polymer based YSPs will afford improved biodegradability, biocompatibility and will also be 
more favorable economically. Current design and preparation of YSPs involve numerous and 
complex steps, elevated engineering temperatures and micron-scaled etching techniques.
23
    
In this study, polymer based magnetic YSPs were engineered with the ability to host multiple 
probes (as model chemical agents). Complex particle engineering was achieved using tri-needle 
co-axial electrospraying which is a single step process. Poly(ε-caprolactone) (PCL) was selected 
as the matrix for both core and the shell materials because of its accepted biocompatibility and 
related drug permeability.
19
 Silicone oil was adopted as the interfacing-layer due to its moderate 
viscosity.
24
 In order to demonstrate co-encapsulation (in seperate compartments) and delivery, 
Nile blue (NB) and acridine yellow (AY) were selected as model hydrophilic probes and Sudan 
red G (SRG) was selected due to its hydrophobic nature. Magnetic nanoparticles (MNPs) (Fe3O4 
~20 nm in diameter) were encapsulated into YSPs (shell layer) to enable magnetic properties. 
YSP composition, interior structure, biocompatibility, dual imaging modality and controlled 
multi-probe release from therein (with and without an external AMF trigger) were investigated.  





 g/mol) and Sudan red G were purchased from Sigma-
Aldrich Ltd., St Louis,USA. Silicone oil (SLO), Fe3O4 (nano-spheres with diameters of ~20 nm, 
MNPs), Nile blue, Nile red, Sodium dodecyl sulfate (SDS) Triton X-100 were obtained from 
Aladdin chemistry Co., Ltd, Shanghai, China. Acridine yellow (neutral) was purchased from 
Shanghai Macklin Biochemical Technology Co., Ltd. Agar was obtained from Shanghai EKEAR 
Bio&Tech Co., Ltd. Phosphate buffer solution (PBS) and glacial acetic acid (HAc) were supplied 
by Sinopharm Chemical Reagent Co., Ltd, Shanghai, China. Ultrapure water was produced with 
a Millipore Milli-Q Reference ultrapure water purifier (Molsheim, France). Modified eagles 
media (MEM, Gibco) and fetal bovine serum (FBS) were obtained from Invitrogen, CA, USA. 
Cell Counting Kit-8 (CCK-8) was purchased from Dojindo Molecular Technologies, Inc 
(Kumamoto, Japan). 
2.2. Fabrication of Yolk-Shell Particles (YSPs) via tri-needle co-axial electrospray 
Figure 1a is a schematic illustration of the tri-needle coaxial electrospray system used for YSP 
synthesis. The nozzle system comprises a set of three stainless steel needles (into one 
concentrically aligned nozzle spraying cylindrical head); three syringe pumps (KD Scientific 
KDS100, USA), a high voltage power supply (Glassman high voltage Inc. series FC, USA) and a 
metallic ground ring electrode (diameter~ 5 cm). For nozzle assembly, the three stainless steel 
needle capillaries possessed inner and outer diameters of 2.85 mm and 2.26 mm for the outer 
capillary, 1.60 mm and 1.07 mm for the central capillary, and 0.50 mm and 0.31 mm for the 
inner capillary, respectively. Media inlets of the three capillaries were connected to the 
corresponding syringes using silicone tubing. The corresponding liquids were injected into 
capillaries by independently controlled syringe pumps. The processing nozzle was connected to 
the high voltage power supply and the metallic ground electrode ring was located directly below 
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the nozzle assembly (5 mm). The power supply was used to provide a static electric field 
between the outlet of nozzle assembly and the ground electrode. A CCD camera (Baumer 
TXG02C, Germany) was connected to image capture hardware (PC) and was used to monitor 
real-time jetting behavior of atomized spray (formed using the tri-needle co-axial electrospray 
system) for stable and near-uniform particle production. The applied voltage was maintained at 
10 kV for all experiments. All YSPs were fabricated using flow rates of 10 ml/h, 2.5 ml/h and 
1.6 ml/h for outer, middle and inner layers, respectively (infusion rates into capillaries). For all 
YSP samples, media for outer and inner layers comprised 20 w/v% PCL dissolved in HAc with 
pre-designated quantities of MNP and hydrophilic model probes (NB or AY). Pure SLO was 
selected for the central interfacing particulate layer along with hydrophobic model probe (SRG). 
The mass ratio of NB:PCL (outer shell), SRG:SLO (central layer) and AY:PCL (inner layer) 
were selected as 7.5, 2 and 12 mg/g, respectively. 
 8 
 
Figure 1. (a) Schematic illustration of the tri-needle coaxial electrospraying system used in this 
study. (b) Digital image of stable jetting behavior from the tri-needle nozzle assembly. (c) 
Formulation, formation and compartments of probe loaded magnetic yolk-shell particles. 
2.3. Characterization 
Optical, fluorescence and scanning electron microscopies (SEM) were used to observe size, 
surface morphology and interior structure of the YSPs. For optical and fluorescent micrographs, 
particles were collected directly onto microscopic glass slides and observed using an optical 
microscope (Pheonix BMC503-ICCF, China) and an inverted fluorescence microscope (Nikon, 
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Ti-S, Japan), respectively. For SEM analysis, YSPs were sprayed on aluminium film and then 
mounted on to a metallic stud using double-sided conductive tape for sputter coating. A thin 
layer of gold under vacuum (Ion Sputter MC 1000, Hitachi, Japan) was deposited for 90s. SEM 
images were obtained using a field emission-scanning electron microscope (FE-SEM, FEI 
Quanta 650 FEG, Hillsboro, Oregon, USA). The diameters of YSPs were analyzed using imageJ 
software (National Institute of Health, USA) directly from electron micrographs. YSP stability 
was assessed in two environments; in air (i.e. storage) and in PBS. YSPs were observed for 
changes to their surface morphology and structure at 1, 3, 5 and 7 days using SEM.  
Sample composition was determined using Fourier Transform Infra-Red (FTIR) spectroscopy. 
Samples were prepared by mixing 2 mg of selected particles with 200 mg of KBr medium by 
grinding and then compressing the resulting powder into transparent pellets (pressure of 12 
MPa).
25
  Pellets were then scanned with FTIR (IR Affinity 1, Shimadzu, Japan) and the spectrum 
was obtained at a resolution of 4 cm
-1
 ranging from 4500 to 500 cm
-1
. Each spectrum was 
obtained using 20 scans.  X-ray diffraction (XRD) was used to confirm successful encapsulation of 
MNPs in YSPs, spectra were recorded with a diffractometer (X'pert 
PRO, Panalytical, Netherlands) equipped with standard Cu Kα radiation source (λ = 1.5405 Å) and 
scanned within 2θ range of 10-90° at a step size of 0.026°. The operating voltage and current were 40 
kV and 40 mA, respectively. Sample magnetization curves were obtained using a vibration sample 
magnetometer (VSM Mini-CFM measurement system, Cryogenic Ltd., UK) at 300K under a 
reciprocating altered magnetic field (-30000 to 30000 Oe), and saturation magnetization was 
obtained from hysteresis loops.  
2.4. In-vitro MRI evaluation.  
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Imaging data was acquired using a 3 Tesla MRI scanner (Magnetom 
Prisma, Siemens Healthcare, Erlangen, Germany) through a 20-channel head-neck coil. MRI 
measurements for two experimental groups and a control sample were obtained. For the first 
group, phantoms contained 4 mg of particulate samples at various MNP:PCL outer layer mass 
ratios (0, 25, 50, 75 mg/g). The second group comprised samples with identical MNP:PCL mass 
ratios (0.5, 1, 2, 4 mg). 4 mg of pure MNPs were used for control experiments. For phantom 
preparation, 1g of agar was added to 100 ml ultrapure water and the mixture was subsequently 
boiled for 30s and cooled. This cycle was repeated until a homogeneous agar gel was obtained, 
which was then allowed to cool further in atmosphere to 40 C. All phantoms to be used for MRI 
were then prepared by mixing particulate samples with 10 ml of the pre-prepared agar gel and 2 
ml 5 w/v% SDS aqueous solution (to improve sample wetting and enhance phantom 
uniformity
26
). Sample-gel mixtures were stirred thoroughly to form a uniform suspension, and 
were then poured into a 15 ml centrifuge tube. Pure agar phantoms (without samples) were also 
fabricated for control experiments. 
T1 mapping was performed using a Siemens WIP (Working In Progress) mp2rage sequence 
(TR/TE =5000 ms/3.37 ms, FA1=4, FA2=5, TI1=700 ms, TI2=2500 ms, FOV=115×75 mm
2
, 
acquisition matrix = 192×192, slice thickness =3 mm). T1-weighted imaging was obtained using a 
spin echo (SE) sequence (TR/TE=2000 ms/6.2 ms, FOV=180×180 mm
2
, slice thickness =4 mm). 
T2 mapping and T2-weighted imaging  were performed using the multi-TE spin echo sequence 
(TR=2900 ms, TE=10.5, 21, 31.5, 42, 52.5, 63, 73.5, 84 ms, FOV=180×73 mm
2
, FA=180, 
matrix size=256×256, slice thickness=2 mm, bandwith=227 Hz/Px). T1 and T2 maps were 
automatically calculated by the system using exponential curve fitting, and mean values were 
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calculated in the regions of interest (ROI), selecting ~50% of total area at the cross section’s 
center. 
2.5. Acoustic characterization 
The setup for acoustic experiments is shown in Figure 2, as utilised in a previous report.
27
 
Pre-weighed particles (0, 2 and 10 mg) with an outer layer  MNP:PCL mass ratio of 75 mg/g 
were suspended using 20 ml ethanol  in a plastic container (2.8 cm in diameter and 3.5 cm in 
depth). A 5 MHz ultrasonic transducer (1.6 cm in diameter and 3 cm in depth) was vertically 
submerged into the suspension (serving as both transmitter and reciever) and was connected to a 
pulser/receiver (5073PR, Olympus Inc., Japan). All signal data from the pulser/receiver was 
acquired and stored using an oscilloscope (200MHz bandwith, WaveSurfer 3024, 
Teledyne LeCroy, USA). Parameters for acoustic experiments were kept constant (PRF=200 Hz, 
Energy=2, Damping=2, Gain=20 dB) and data was processed using Matlab 2013b 
(The Mathworks Inc., Natick, USA). 
 
Figure 2. Acoustic experimental setup. 
 12 
2.6. Probe loading capacity and encapsulation efficiency 
The loading capacity (LC) of selected probes was determined as the quantity of probe 
encapsulated within YSPs and was calculated using Equation 1. The encapsulation efficiency 




Weight of encapsulated probe
Weight of YSPs
×100% , (Eqn.1) 
EE (%)=
Weight of encapsulated probe
Weight of initial added probe 
×100% , (Eqn.2) 
2.7. In-vitro probe release and AMF application 
Probe release profiles from various YSP layers were investigated in vitro. For this, 30 mg of 
NB and AY loaded (or alternatively SRG) YSPs were suspended using 10 mL release medium, 
respectively, which comprised PBS (pH=7.2) and 0.5 w/v% SDS to maintain sink conditions
29
  
in a 10mL glass vial. Probe release in static or AMF triggered environments at the ambient 
temperature (~23.5 C) were assessed. A strong magnet was applied in close proximity to the 
base of sample hosting vials to completely separate YSPs from test-medium; and then 4 mL of 
supernatant was collected. This procedure was performed at pre-determined time intervals. 
Supernatant concentration was determined using UV-Vis spectroscopy (UV-2600 
spectrophotometer, Shimadzu, Japan).
12
 Removed analyte samples were replaced with 4 mL of 
fresh release medium (PBS). For AMF trigger application, a copper solenoid coil (45 turns) was 
laced around a plastic tube and driven by a power amplifier (HFVA-42, Foneng Science and 
Technology Co., Ltd., Nanjing, China).  A functional signal generator (AFG1022, Tektronix, 
USA) was used to produce a small sinusoidal signal, which was then amplified to generate an 
AMF around the coiled tube. The sample hosting vial was placed in the coiled tube’s hollow core, 
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which ensured YSPs were subjected to the applied AMF. All other conditions were constant. The 
effect of both frequency and power on probe release was investigated. All experiments were 
performed in triplicate. 
In order to examine potential thermal impact (arising from AMF generation) on YSPs, a Ti32 
thermal camera (Fluke Corporations, Seattle, USA) was deployed to image the process at pre-
determined time intervals. Data was analyzed using SmartView software to extract temperature 
field distribution, which was subsequently used to calculate mean temperature. 
2.8. In vitro cell culture and biocompatibility 
YSP biocompatibility and potential cytotoxic effects were evaluated using in vitro cell culture. 
L929 mouse fibroblasts were propagated in MEM medium with 10% heat-inactivated FBS and 1% 
(v/v) antibiotic–antimycotic in a petri dish which were incubated at 37 °C in humidified 
CO2 (5%) environment.  
For biocompatibility assessement, cells were incubated for 24 h. The culture medium was 
replaced with 3 mL of fresh medium containing magnetic YSPs at varying concentrations (0, 1 
and 5 mg/ml). For this, an YSP outer shell MNP:PCL mass ratio of 75 mg/g was selected. After 
24 h, cells were visualized using fluorescent counterstaining with rhodamine-phalloidin and 
DAPI to observe morphology and confirm cellular state. Treated cells were washed with PBS 
three times and fixed with 4% paraformaldehyde for 30 min. Cell permeabilization was achieved 
using 0.1% Triton X-100 for 5 min followed by washing with PBS, and the procedure was 
carried out three times. Rhodamine-phalloidin (1:200 in PBS) was used to stain filamentous actin 
skeleton for 20 min and then DAPI (1:5000 in PBS) was used to stain cell nuclei for 5 min. After 
this, cells were imaged using inverted fluorescent microscopy. 
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YSP cytotoxicity was evaluated using CCK-8 assay. Magnetic YSPs possessing an outer shell 
mass ratio (MNP:PCL) of 75 mg/g were sterilized under UV light. 100 μl of uniform cell 
suspension was seeded in 96-well plates and incubated with YSPs at two selected concentrations 
(1 and 5 mg/ml) for designated time intervals (1, 2, 4, 8 and  24 h). Seeded cells containing no 
particulate samples were maintained as control. The culture medium was subsequently removed 
and 100 μl of CCK-8 solution (1:10 diluted by MEM) was added to each well and incubated for 
a further 3 h at 37 C. The optical density (OD) of each well (at 450 nm) was recorded on a 
microplate reader (VersaMax, Molecular Devices, USA). Cell viability results were presented as 
the average cell viability [(ODsample − ODblank)/(ODcontrol − ODblank) × 100%] of quadruplicate 
wells.  
3. RESULTS AND DISCUSSION   
3.1. Synthesis of magnetic yolk-shell particles 
Synthesis of magnetic YSPs was achieved via tri-needle coaxial electrospray setup as shown 
in Figure 1a. Formulated media were infused into outer, central and inner capillaries at flow 
rates of 10, 2.5 and 1.6 ml/h, respectively. Under co-flowing conditions (all three formulations 
infused continously) with application (and increments) of voltage field strength, typical 
transitions of liquid deformation at an electrospraying nozzle exit are observed. In this instance, 
four jetting modes are encountered: dripping mode, coning mode, stable cone-jet mode and 
multi-jet mode
24
. The stable cone-jet mode is optimal and is ideal for near-uniform YSP 
production with intact shell morhology and a well-defined interior structure (obtained at ~10 kV) 
as shown in Figure 1b. Figure 1c shows YSP formulation, architecture and compartments. 
Three media were infused into the tri-needle coaxial nozzle and stable jetting was observed. 
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Interestingly, the compound jet comprised polymer solutions at inner and outer flows; 
sandwiching the oil in the central layer compartment. The jetting stability was reminiscent to 
those osberved for single and conventional two-needle coaxial electrosprays. This indicated 
YSPs would possess near uniform structures with neat core-shell encapsulation.  
3.2. Particle structure and morphology 
The external morphology and interior arrangement of YSPs were assessed comprehensively. 
Figure 3a shows optical micrographs of YSPs, which demonstrate a near-uniform size 
distribution and the inset in Figure 3a eludes to the multi-compartment strucutre (i.e. particle in 
particle). A merged bright field and fluorescent YSP image is shown in Figure 3b. Particles 
consist of a polymeric core, an oily interfacing layer (silicone oil) labeled with Nile red, and a 
polymeric outer shell, and the overall strucure is well-defined with the central component hosting 
probe only. Electron micrograph in Figure 3c shows YSPs to be spherical possessing a smooth 
surface shell and this also confirms neat layered encapsualtion of MNPs. Figure 3d further 
indicates the co-flow engineering process was stable, as YSPs possess near uniform size 
distribtiion (mean diameter=13.5±1.74 μm). The electron micrograph shown as Figure 3e 
highlights a ruptured YSP which may have arisen due to sporadic MNP agglomeration which 
impedes polymer layering ability during processing on the micron scale. This, however, 
confirmed the anticipated yolk-shell structure (particle in particle) as evidenced in the 
micrograph. Figure 3f is an electron micrograph showing the cross section of a YSP embedded 
in epoxy resin. In this instance, the core shell merged with the epoxy resin and the void space 
between the core and the outer shell indicates the existence of the interfacing oily layer. YSP 
morphology for samples assessed in air and PBS at 1, 3, 5 and 7 days, respectively, is shown in 
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Figure 3g. The shape and surface morphology of YSPs show negligible change over 7 days, for 
both environments, indicating acceptable stability. 
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Figure 3. Morphological characterization of yolk-shell particles. (a) Optical micrographs (b) 
Merged bright-field and fluorescent image of yolk shell particles with the interfacing layer 
labeled with Nile red. (c) electron micrographs of yolk shell particles and (d) size distribution 
based on statistical analysis of 300 particles (e) electron micrograph of ruptured micro-particle (f) 
Cross-section electron micrograph of microsphere embedded in epoxy resin. [scale bar in (c) =10 
μm]. (g) electron micrographs of yolk-shell particles in air for 1, 3, 5 and 7 days (I-IV, 
sequentially) and in PBS for 1, 3, 5 and 7 days (V-VIII, sequentially). [scale bar in (g) =30 μm] 
3.3. Chemical composition of yolk shell particles 
FTIR spectroscopy was used to confirm the composition of  several formulated YSPs (Figure 
4a-d) and the spectra of pure MNPs and model probes is shown in Figure 4e-h. MNP presence 
is confirmed by the peak at 1551 cm
-1 
(Figure 4e) and by comparing spectra for magnetic 
(Figure 4c) and non-magneitc (Figure 4d) YSPs; loading of the funcitonal material is confirmed. 
Characteristic peaks of NB (Figure 4f) and AY (Figure 4g) are identified in multi-probe loaded 
YSP samples (Figure 4a) at 2362 and 3739 cm
-1
, respectively. The characteristic peak for probe 
SRG (Figure 4h) is identified in SRG-loaded YSPs at 1185 cm
-1
. The presence of all 
formulation components was confirmed, suggesting the tri-needle co-axial electrospying to be 




Figure 4. FTIR spectrum of (a) NB and AY loaded magnetic yolk-shell particles, (b) SRG 
loaded magnetic yolk-shell particles, (c) Magnetic yolk-shell particles, (d) yolk-shell particles 
without MNPs (e) Pure MNP powder, (f) Pure NB powder, (g) Pure AY powder and (h) Pure 
SRG powder. 
3.4. Magnetic properties 
XRD was used to confirm successful encapsualtion of MNPs in YSPs. Figure 5(a) shows the 
XRD spectra of magnetic YSPs with MNP:shell concentration ratio of 75 mg/g. The diffraction 
peaks for MNPs (2 angle) at 30.1, 35.5, 43.1, 57.0, 62.6 are indexed as (220), (311), (400), (511) 
and (440) diffraction plane, respectively, which match well with the values of the standard card 
(JCPDS card 79-0419)
30
 , indicating the incorporation of MNPs in YSPs.   
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Figure 5(b) shows hysteresis loops for magnetic YSPs prepared with varying MNP: shell 
concentration ratios (25, 50, 75 mg/g). Corresponding saturation magnetization values were 
1.426, 2.918 and 4.263 emu/g, respectively. Saturation magnetization correlated with MNP 
content in the outer shell (noted as: 1:2:3), which indicates magnetic properties of YSPs can be 
enhanced directly by increasing functional nano-material content during multi-needle 
electrospraying. Hysteresis loops show negligible coercivity and remanence magnetization which 
further indicates MNPs are generally dispersed within the shell thus forming a single domain
31
. 
Magnetic properties of YSPs were further confirmed by applying a strong magnet to a vial 
hosting the engineered samples as a suspension (NB-AY loaded YSPs in PBS release medium 
with 0.5 w/v% SDS) (Figure 5(b), inset). With no applied magnetic source (middle vial), YSPs 
sediment to the base of the vial after several minutes due to their density (1.0710 g/cm
3
) being 
greater than the release medium (1.0099 g/cm
3
). The sedimentation of particles causes some 
agglomeration doe to the hydrophobic nature of PCL polymer.  Upon application, particulate 
samples migrated rapidly towards the magnetic source forming a cluster. This provides a 
relatively quicker method to separate particles from dissolved/diffused active in test medium (i.e. 
compared to high speed centrifugation and precipitation, which may also potentially lead to an 
increase in release from the carrier system
32
). Furthermore, the ability to move and direct YSPs, 
using a small yet powerful magnet, indicates clear potential for localised drug delivery and 
targeting.  
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Figure 5. (a) XRD spectra of the magnetic YSPs. (b) Magnetization curves of yolk-shell 
particles with varying MNP loading content in the outer layer (the legend indicates outer shell 
mass ratio of MNP:PCL). Inset shows a digital image of particle displacement using a small 
external magnet. 
3.5. In-vitro MRI evaluation 
To evaluate YSP potential as an MRI contrast agent, a series of agarose phantoms were 
prepared.  Two main factors were investigated. In the first instance, different quantites of YSPs 
(0.5, 1, 2 and 4 mg) were assessed. The second set focused on varying shell MNP:PCL mass 
ratios (0, 25, 50, 75 mg/g). For both cases, YSPs were fabricated and both quantitative MRI T1- 
and T2-mapping were explored. Furthermore, MRI T1- and T2-weighted images were also 
measured. 
Figure 6a shows T1 maps (rows 1-2 ) and T1-weighted images (rows 3-4), while Figure 6d 
shows T2 maps (rows 1-2) and T2-weighted images (rows 3-4). The signal intensity increased 
with an increase in MNP content (from 0 to 75 mg/g) or sample quantity for T1-weighted images. 
Signal intensity decreased with an increase in MNP content (from 0 to 75 mg/g) or sample 
quantity for T2-weighted images. Figure 6b and c indicate that T1 relaxation time decreases as 
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MNP content (shell mass ratio, MNP:PCL) or the quantity of magnetic YSP samples is increased. 
Both trends show a good linear fit, which demonstrates encapsulated MNPs shorten T1 relaxation 
time. Figure 6e and f suggest that MNPs also reduce T2 relaxation time, which is more notable 
than the impact on T1 with curves exhbiting a good linear fit. The results show magnetic YSPs 
have clear potential as contrast agents for both T1 and T2 MRI imaging. 
 
Figure 6. In vitro MRI data (a) T1 maps (rows (1) to (2)) and T1-weighted MRI images (rows (3) 
to (4)). (b) and (c) are linear fits of 1/T1for phantoms comprising 4 mg of particle samples with 
varying MNP:PCL shell ratios and varying overall particle quantities using a shell MNP:PCL 
ratio of 75 mg/g. (d) T2 maps (row (1) to (2)) and T2-weighted images (row (3) to (4)). (e) and (f) 
are linear fits of 1/T2 for phantoms comprising 4 mg of samples with varying shell MNP: PCL 
ratios and particle quantities (using a fixed shell MNP:PCL ratio of 75 mg/g). 
3.6. In vitro acoustic characterization  
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To evaluate YSP potential as an US contrast agent, acoustic properties of magnetic YSPs (75 
mg/g MNP:PCL ratio in the outer shell) at various concentrations (0, 2  and 10 mg/ml) were 
measured using experimental setup illustrated in Figure 2. The frequency spectra demonstrates 
acoustic performance is enhanced by increasing YSP concentration in the test sample near the 
centre frequency, as shown in Figure 7. Here, ethanol was used as the test medium instead of 





Figure 7. Echo signal frequency spectra of suspensions with varying particle loading volumes in 
ethanol. 
3.7. Multiple in-vitro probe loading and release from various particle compartments 
The probe loading capacities (LC) of NB, SRG and AY are 0.272 %, 0.078 % and 0.073 %, 
respectively. The encapsulation efficiencies (EE) of NB, SRG and AY are 88.6 %, 79.3 % and 
 23 
92.1 %, respectively. Independent release profiles of multiple probes (selected as model agents) 
from magnetic YSPs were comprehensively studied. Over the last two decades, explorations into 
synergistic chemotherapies (utilizing two or more actives) to treat various types of cancers have 
broadened, and numerous efforts have focused on the role and development of advanced carriers 
systems.
17-18, 33-34
 For drug carrier design; hydrophilicity of incorporated active is a crucial factor, 
not only for matrix dispersibility but to achieve ideal therapeutic release.
16, 35
 Therefore, 
development of advanced carrier systems capable of delivering active(s) with varying 
hydrophilicities  is extremely valuable. In addition to delivery, a process which enables 
encapsulation of a broad range of chemical agents is also desirable  due to formulation barriers.   
In order to demonstrate hydrophobic and hydrophilic agent encapsulation; single-step co-
encapsulation (and subsequent co-delivery) from a single carrier was demonstrated. NB and AY 
probes were selected as model hydrophilic agents and SRG was chosen as the hydrophobic 
component. To ensure accuracy for release measurments (overcoming any issues arising from 
key overlapping characteristic peaks), NB & AY probe loaded YSPs (and SRG loaded YSPs) 
were fabricated independently. For NB and AY co-loading, NB was dispersed into the outer 
polymeric shell and AY was incorporated in to the inner core. For SRG loading into YSPs, the 
compound was mixed with SLO in the interfacing oily layer, as a single agent delivery system.  
A schematic illustration and corresponding UV-vis spectra from the two deployed  samples is 
shown in Figure 8a and b. The spectrum in Figure 8a shows the maximum absorption peaks of 
NB and AY, which were identified at 637 and 460 nm, respectively. Figure 8b shows the 
maximum absorption peak of SRG (509 nm) which exhibits a relatively high absorption range 
(350 to 650 nm); and this shoulders peaks for NB and AY. Standard calibration curves for 
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various probes (NB, AY and SRG) are shown in Figure 8c-e. A good linearity and fit for data 
points was achieved ensuring release kinetic readings were reliable and accurate. 
 
Figure 8. Graphic representations of yolk-shell particles and  corresponding UV-vis spectra of 
probe hosting supernatants obtained from release medium (a) NB-AY and (b) SRG. (c), (d) and 
(e) are standard calibration curves for probes NB, AY and SRG at their maximum absorption 
peak values (637.5, 460.5 and 509 nm, respectively). 
Probe release profiles over a 7 day period at ambient temperature (23.5 C) and under  static 
condition’s (control, no AMF trigger) are displayed in Figure 9a. NB displayed the most rapid 
release rate in the first 12 h (84.6%) and greatest final release quantity (97.8%) after 7 days. 
Quantities of AY and SRG released were 64.1 and 53.1%, respectively, at the first 12 h and the 
total final released quantity of these compounds  were 86.1 and 64.9%, respectively. The 
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relatively low release rate of SRG is attributed to its high solubility in SLO and poor solubility in 
the aqueous release medium, which retained a considerable portion of the probe (35.1%) in YSPs 
post 7 days assessemement.  
 
Figure 9. Cumulative probe release profiles with and without AMF exposure (a) Long-term 
release of probe (for seven days) without AMF (control group). (b), (c) and (d) comparison of 
probe release (NB, SRG and AY, respectively) without AMF (CTRL)  and with external AMF at  
low (LAMF) and high (HAMF) power for 12 h. Insets in (b)-(d)  show magnified views of data 
points between 0~2 h, and designated release stages are highlighted in different colours. 
Figure 9b, c and d show release behavior of NB, SRG and AY probes under the infleunce of 
an external AMF using two power settings (LAMF: 0.7 mT and HAMF: 1.4 mT) at 40 kHz, 
respectively. The release of both hydrophilic compounds, NB (Figure 9b) and AY (Figure 9d), 
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is enhanced compared to the control group when magnetic YSPs are exposed to an external AMF. 
This is attributed to AMF interaction with co-encapsulated MNPs, which produces heat due to 
hysteresis, Néel and Brownian relaxation upon exposure to AMF
36
. In addiiton, probe release is 
more pronounced when the higher AMF power setting is deployed (HAMF, 1.4 mT). For 
hydrophobic probe (SRG, Figure 9c) the greaest release rate is observed at the HAMF. However, 
the lowest SRG release rate was obtained using low power AMF setting (LAMF, 0.7 mT); and 
was more sustained than the control group (no AMF  trigger deployed). It is interesting to note 
that SRG release behavior is different to other probes under an AMF, with contrasting 
hydrophillicities (e.g. NB and AY).  AMF action leads to magnetic YSP compression and 
exertion against the particle shells surface, which in turn impacts adjacent YSPs.
32
 In this regard, 
for oil-phase compartment, the volume of encapsulated central medium is “locked” in the YSP 
structure and inhibited from direct contact with the surface. Therefore, although the temperature 
of intra-particle oil-phase may increase moderately (from 23.5 to 28.0 C) upon exposure to 
LAMF, the release of hydrophobic probe is actually impeded by micron-scaled barrier function. 
In addition, magnetic compression induced “inversion”, which is defined here as reduced drug 
release rate phenomenon upon AMF application, was observed and is highlighted in Figure 9b-d 
insets. The inset background color indicates different release phases for each probe in the first 2 
h, with variations arising to phases based on test parameters. As represented, particles in the 
HAMF group do not always exhibit fastest probe release rates. Likewise YSPs in the control 
group do not release probe at the slowest rate; indicating probe release cannot be confined to a 
single law in general. At initial release study stages (< 2 h), probe release from all non-triggered 
YSP specimens is greater than outcomes observed for both LAMF and HAMF treated samples. 
At intermediate phases, probe release rate from LAMF and HAMF triggered groups become 
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comparable to non-triggered samples. In general, multiple-probe release from magnetic YSPs is 
a complicated process governed by several mechanisms (e.g. dissolution, diffusion and AMF 
induced effects). The interesting “inversion” aspect, which is often missed due to the enhanced 
active release impact from temperature rise, is observed at LAMF and is documented in this 
study.  
Data obtained for multi-probe release kinetics were fitted to the Korsmeyer-Peppas model to 
determine potential release mechanisms. The model is expressed as shown in Equation 3.
37
     
Mt/M∞=kt
n
 ,  (3) 
Here, Mt/M∞ is the fraction released drug at time t, k is the release rate constant, and n is the 
release exponent. In this model, the value of n is used to postulate the release mechanism. For a 
spherical matrix, n ≤0.43 corresponds to Fickian diffusion, 0.43 < n < 0.85 to anomalous 
transport, n = 0.85 to case II (relaxational) transport, and n > 0.85 to super case II transport. Data 
were plotted as log cumulative percentage drug release versus log time for the first 4 h of probe 
release (the fraction of released probe ranged from 45 to 65%). The fitting parameters obtained 







Table 1  
Fitting parameters for probe release from yolk shape particles. 
Drug-Mode 
Korsmeyer-Peppas Model 
Equation  n R
2
 
NB-CTRL log(Mt/M∞*100)=0.2436+0.6510*log(t) 0.6510  0.9962  
NB-LAMF log(Mt/M∞*100)=-0.3625+0.9423*log(t) 0.9423  0.9750  
NB-HAMF log(Mt/M∞*100)=-0.6928+1.1066*log(t) 1.1066  0.9675  
AY-CTRL log(Mt/M∞*100)=0.6134+0.4872*log(t) 0.4872  0.9868  
AY-LAMF log(Mt/M∞*100)=0.4721+0.5389*log(t) 0.5389  0.9708  
AY-HAMF log(Mt/M∞*100)=0.1815+0.6764*log(t) 0.6764  0.9150  
SRG-CTRL log(Mt/M∞*100)=0.3517+0.7015*log(t) 0.7015  0.9456  
SRG-LAMF log(Mt/M∞*100)=0.4399+0.6058*log(t) 0.6058  0.9289  
SRG-HAMF log(Mt/M∞*100)=0.4775+0.6309*log(t) 0.6309  0.9778  
 
According to fitting parameters, only NB-LAMF and NB-HAMF probe release profiles follow 
super case II transport, while all other release kinetics indicate anomalous transport.
38
 This 
difference is attributed to co-disperion of NB and MNPs within the same YSP layer 
(compartment). Upon application of an external AMF (to YSPs), heat production from magnetic 
energy dissipation as Brown and Néel relaxations, mechanical vibration and motion induces 
stress in the shell layer of YSPs. The impact of these relaxations and other heat induced effects 
result in alteration to the polymeric shell microstructure.
39
 In contrast, although AY and SRG 
probes are also affected by generated heat, resulting stress towards the shell is lower due to 
encapsulation in non-MNP compartments. The impact of varying AMF frequencies (20, 40 and 
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80kHz) on probe release profiles were also investigated to further confirm “inversion” aspects in 
the first 2 h (Figure 10a-c).  NB and AY probes exhibit “inversion” phenomena at 20, 40 and 80 
kHz, while this was only present at 20 KHz for SRG. The finding indicates the “inversion” is a 
universal mechanism regardless of probe hydrophilicity. The real time in-situ temperature of 
particulate samples exposed to HAMF is shown in Figure 10d. Thermal graphs demonstrate near 
identical temperatures for all release media hosting various YSP samples. The temperature 
increases rapidly during the first 2 h (23.5 to 31 C) and then a gradual increment is observed, 
eventually reaching 33 C over the next 4 h. This confirmed MNPs induce heat upon exposure to 
AMF, which is an important factor in enhancing model probe release.  
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Figure 10. Cumulative release profiles of model probes with external AMF at varying 
frequencies. (a), (b) and (c) are probe release profiles with (20kHz, 40kHz and 80kHz) and 
without AMF (CTRL)  (d) shows thermally imaged temperature-variation curve of selected 
sample vials over 4 h. Inset shows the setup used for the release process treated with external 
AMF. 
3.8. Cell culture and fluorescent microscopy 
To assess biocompatibility, cells were incubated with YSPs for 24 h at various concentrations 
(0, 1 and 5 mg/ml). For this YSPs possessing a shell MNP:PCL ratio of 75 mg/g MNPs were 
fixed and counterstained using DAPI for nuclei and rhodamine–phalloidin for cytoskeleton. 
Fluorescent images are shown in Figure 11, which indicate negligible cytotoxicity. Probe loaded 
YSPs were not assessed due to their fluoresecing nature and their well documented toxicity. 
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Figure 11. Cells incubated with yolk-shell particle samples at varying concentrations over 24 h. 
Figures in left and central columns are fluorescent micrographs of nuclei stained with DAPI 
(blue) and cytoskeleton stained with rhodamine-phalloidin (red). Merged images are shown in 
the right column.  
3.9. Cell viability 
Cells incubated with YSP samples (using various particle concentrations and incubation times) 
were quantitatively assessed using CCK-8 assay. As shown in Figure 12, YSPs exihibit 
negligible toxicity toward cells and a slight improvement in cell viability at 4, 8 and 24 h 
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incubation times was observed when compared to the control group (culture medium alone), 
indicating excellent biocompatibility. However, at an incubation time of 24 h, cell viability at a 





Figure 12. Cell viability with varying quantities of magnetic yolk-shell particles over designated 
time periods. 
4. CONCLUSIONS 
In summary, multiple probe hosting magnetic YSPs were successfully synthesized via tri-
needle coaxial electrospraying. The surface morphology and interior structure of YSPs were 
demonstrated using fluorescent, optical and scanning electron microscopy. Magnetic properties 
and chemical composition of YSPs were confirmed by VSM and FTIR, respectively. In-vitro 
MRI/US dual-imaging modality and AMF triggered controlled release (for both hydrophilic and 
hydrophobic probes) were demonstrated. YSPs exhibit clear potential as synergistic micron-
scaled platforms for theranostic applications. Cytotoxic experiments confirmed acceptable 
biocompatibility. Finally, in addition to their structural design, the facile engineering process is 
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valuable for sensitive active pharmaceutical ingredients where product forming is required, 
ideally, in a single step at ambient environments.   
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